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Abstract 
 
Among children and adolescents diagnosed with cancer today in many high-income 
countries, 5-year net survival is approximately 80%. This is encouraging as it shows what 
is possible.  Unfortunately, the limited available data from low- and middle-income 
countries (LMIC), where nearly 90% of children with cancer live, suggest global survival 
is substantially worse. As LMIC are undergoing rapid epidemiological transition, with a 
shifting burden from infectious to non-communicable diseases, cancer care for all ages 
has become a global focus. To improve outcomes for children and adolescents diagnosed 
with cancer worldwide, an accurate appraisal of the global burden of childhood cancer is 
a necessary first step. In this study, we reviewed four worldwide studies of the global 
cancer burden that included data on children and adolescents. Each study used a variety 
of overlapping and nonoverlapping statistical approaches and outcome metrics. 
Moreover, to provide guidance with the aim of improving future estimates of childhood 
global cancer burden, we also propose several recommendations to strengthen data 
collection and standardize analyses. Ultimately, these data may aid stakeholders in 
developing plans for national and institutional program development, with the overall aim 
of helping to reduce the global burden of cancer in children and adolescents. 
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Background 
 
Virtually fatal 50 years ago, cancer in children can now be successfully treated in 
approximately 80% of cases where there is ready access to modern treatments and 
robust supportive care.(1) However, only 10% of the world’s children live in the high-
income countries (HIC) where effective care is broadly accessible.(2, 3) Over the past 
decade, the widening divide in cancer care and outcomes between HIC and the rest of 
the world has garnered significant attention, especially for adult cancers where both 
prevention and early intervention represent viable, cost-effective opportunities to prevent, 
treat and palliate cancer.(4) Children with cancer, however, represent a small proportion 
(around 1%) of all cancers diagnosed worldwide each year, nearly all of which are 
currently not amenable to a defined prevention strategy. Unfortunately, children are often 
neglected in cancer control planning efforts, despite a disproportionately high number of 
person-years of life lost due to missed opportunities to diagnose and treat cancer in low- 
and middle-income countries (LMIC).(5-7)  
 
The magnitude of the global burden of childhood and adolescent cancer remains poorly 
quantified. There are currently no global estimates of incidence, survival and mortality for 
children with cancer in a vast majority of LMIC. Creating sound estimates of the global 
burden of childhood cancer is challenging due to the paucity of high-quality cancer 
registration and vital statistics data in LMIC as well as the differences in the etiology, 
pathogenesis and presentation of the most common neoplasms between children and 
adults.  
 
Up-to-date and accurate epidemiologic data are critical for prioritization and health policy 
decisions, and in developing meaningful national cancer control plans or strategies. 
Effective planning for estimating resource needs (financing, health workforce, 
infrastructure, medicines, diagnostics and health technologies) and in the organization 
and delivery of health services, depends on understanding how many children will 
develop and survive cancer, and what types of cancers and long-term effects from 
cancer-directed treatment can be expected. To assess the available data on the global 
burden of cancer in children, we compared the data sources and methodology of all major 
studies in children and adolescents (ages 0-19 years). We have also identified key 
requirements for complete and accurate burden estimates.  
 
Data Collection 
 
Search strategy and selection criteria  
 
To identify studies describing any element of global childhood and adolescent cancer 
burden, we conducted a scoping review of the published literature using a modified 
PRISMA 2009 approach.(8, 9) Rather than relying solely on expert knowledge, a decision 
was made to conduct a scoping review in order to ensure a thorough investigation of the 
literature was completed. Adaptations were based on scoping review guidelines and 
recommendations (search strategy available in the appendix page 2).(10) Inclusion and 
exclusion criteria were developed in advance of the search. Criteria for inclusion were 
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that studies: contained data on cancer patients up to 20 years of age; reported data for 
at least two of the ten most common malignancies in children based on Surveillance, 
Epidemiology and End Results Program (SEER) rankings in the United States(1); 
obtained primary data from population-based cancer registries or vital registration 
systems; described at least one of the following measures: incidence, survival, 
prevalence, or mortality; reported results from at least three World Health Organization 
(WHO) regions; and publication was between January 2000 and February 2018. Criteria 
for exclusion publications in non-English, from the same research program, or were 
review articles. As we assumed studies inclusive of data from multiple regions would 
require significant global collaboration, the decision to include only English language 
publications was considered tenable. Databases searched were PubMed, Medline via 
Web of Science, and SCOPUS. All abstracts identified by the search were reviewed for 
inclusion.  
 
Sources of data used  
 
A total of 987 abstracts were reviewed. After evaluation, five major research programs 
that have estimated the burden of cancer within the 0-19 year age-range in at least three 
WHO regions were identified: International Incidence of Childhood Cancer (IICC-3)(11, 
12), GLOBOCAN (2012)(13), Global Burden of Disease (GBD 2016)(14), CONCORD 
(CONCORD-3)(15), and SurvCan.(16) Among the five programs, all but SurvCan used 
the conventional age categories for children (0-14 years) or children and adolescents (0-
19 years). SurvCan included data on patients diagnosed during 1990-2001 in 14 countries 
in Africa, Asia, the Caribbean and Central America, but children and adolescents were 
included in a broad age range with young adults (< 45 years old). Thus, as it was 
impossible to determine childhood cancer survival from the published data, SurvCan was 
excluded from this review.  
 
Approaches used  
 
Table 1 highlights the methods applied, the main burden measures reported (incidence, 
survival, and mortality) and the differences in methodology between the selected studies. 
IICC-3 and CONCORD-3 reported observed data on cancer incidence and survival, 
respectively, from countries or regions covered by population-based cancer registries. 
GLOBOCAN 2012 and GBD 2016 used observed data and a range of sources as inputs 
to various statistical models to produce selected subnational (GBD only), national, 
regional and global cancer burden estimates.  
 
Findings 
 
Incidence measures from IICC-3 
 
The results and methods from the IICC-3 study were published and made available as 
open-access online in 2017; childhood and adolescent cancer incidence were reported 
as age-specific and age-standardized incidence rates by sex and age groups (i.e., ages 
0-14 years and 15-19 years).(12) Data were requested from all known population-based 
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cancer registries but only included if they met a defined set of quality criteria, with 72% 
(308/420) of submitted registry datasets meeting these standards. A subset of the 
available data, covering the entire period from 2001-2010, was used to provide pooled 
incidence rates, grouped into 19 strata by world regions and, when possible, ethnic 
groups.(11)  IICC-3 is unique among the global studies of childhood cancer incidence in 
that individual patient data were collected from population-based cancer registries and 
that all the included cancer cases were classified and presented using the third edition of 
the International Classification of Childhood Cancer (ICCC-3).(17)  
 
With the limited but high-quality data available through IICC-3, exploring the scope and 
objectives of the study highlights some opportunities for future research. First, we show 
a map of the national and sub-national population-based cancer registry coverage based 
on high-quality data included in the IICC-3 and that were made available as open-access 
online by the research program (Figure 1).(12) National and subnational coverage data 
for incidence was available through 308 registries. The map shows that a large proportion 
of LMIC countries in Africa and central and south-east Asia either did not submit or 
produce high-quality cancer registration data for children with cancer. To obtain an 
accurate appraisal of the current and future disease burden in addition to ancestry-
specific genomic determinants of childhood cancer risk, it will be critical to develop more 
high-quality population-based registries in LMIC.(18-21) Second, the data reported are 
reflective of the patients registered in the participating registries. Although 11.4% of the 
global population of children was covered by registries included in the analysis for 2001-
2010,(11) the overall incidence were weighted towards those observed in the well 
covered areas.  
 
Survival estimates from CONCORD-3 
 
CONCORD-3 is the only study of the global cancer burden to report cancer survival 
among children. It provided five-year net survival estimates for children (0-14 years) 
diagnosed with ALL, lymphomas and brain tumors during 2000-2014 with complete 
summary tables by registry available in the supplementary appendix to the 
publication.(15) Additional data including life tables and tools for analysis are included on 
the CONCORD website.(22) Although AML was not included in CONCORD-3, a separate 
sub-analysis using CONCORD-2 data recently provided five-year net survival estimates 
for both ALL and AML up to 2009.(23)  
 
CONCORD-3 includes individual patient data from population-based cancer registries. 
Centralized data quality checks were performed, including the standard quality checks 
similar to those used in IICC-3 and quality checks specific for survival analysis. Summary 
quality control indicators were published for each cancer, country, registry and calendar 
period.(15)  
 
Similar to IICC-3, cancer data were submitted by registries using the third edition of the 
International Classification of Diseases for Oncology (ICD-O-3) for all or part of the 15-
year period 2000-2014. Age-standardized net survival, a measure of the probability of 
cancer patients to survive their cancer after controlling for competing risks of death 
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(background mortality), was estimated at five years after diagnosis by a cohort approach 
for patients diagnosed between 2000-04 and 2005-09, and by a period approach for 
patients diagnosed between 2010-14, where less than five years of follow-up data were 
available.(24) In order to use net survival as a metric to account for the very wide variation 
in background mortality between populations and over time, life tables for all-cause 
mortality, by single calendar year, sex, age and, where possible, race or socio-economic 
status, were constructed for each population covered by any registry participating in 
CONCORD-3.(25) Five-year trends in survival were generated where data was available. 
 
The gaps that remain after completion of the CONCORD-3 study are similar to those 
noted for IICC-3. Additionally, solid tumors, which represent approximately one-third of 
childhood cancers in HIC, have not yet been included in the CONCORD program. Finally, 
the observed survival among children in low and low-middle income countries remains 
unknown due to the lack of quality data from population-based cancer registries in these 
settings. 
 
GLOBOCAN and the Global Burden of Disease study (model-based approaches to 
the estimation of the global cancer burden in children and adolescents) 
 
Estimating national, regional, and global cancer burden has a long history and includes 
the studies conducted at International Agency for Research on Cancer (IARC) since the 
1980s as a prelude to the multiple GLOBOCAN editions and GBD estimates. Both 
GLOBOCAN and GBD estimated incidence, mortality, and prevalence of cancers for all 
countries, age-groups, and both sexes covering the entire life-span. The GBD study also 
produced estimates for cancers from 1990 to 2016 and also reported person-years lived 
with disability, person-years of life lost, and disability-adjusted life years (DALYs), a metric 
that accounts for both the fatal and non-fatal components of disease burden.(6, 26) A 
comparison of the different outcomes reported is available in Table 1.  
 
Data sources 
 
The differences in GLOBOCAN and GBD source data and analytic approach are 
summarized in Table 2. For both studies, population-based cancer registry data and vital 
registration systems data were used.(27) The GBD study also included verbal autopsy 
data for selected cancers.(28) The data sources for GBD and GLOBOCAN included the 
published registry data from Cancer Incidence in Five Continents (CI5),(29) a series of 
monographs, produced by IARC and the International Association of Cancer Registries, 
with the objective to make available comparable data on cancer incidence from a wide 
range of geographical locations, and other publicly available data sources. Both studies 
preferentially used all available data, rather than excluding data of lesser quality data, 
because the lesser-quality data may have reflected incidence or mortality patterns to 
some extent. GLOBOCAN developed an alphanumeric scoring system to indicate the 
quality of available data for incidence and mortality separately by country.(13) The GBD 
also used a rating system to describe the mortality data quality.(26) Finally, given the 
complexity of the multiple statistical models used, the 2016 GBD cancer burden report 
includes charts detailing fulfillment of and compliance with the GATHER guidelines.(30) 
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In addition, data sources used, descriptive flowcharts and references to the 
corresponding statistical methods used to generate the estimates are included in the 
supplementary materials.(6)   
 
Model-based approaches 
 
The GLOBOCAN and the GBD studies both estimated incidence, mortality, and 
prevalence, but the methods applied to model these estimates differ substantially. For the 
GLOBOCAN study, a two-pronged stepwise approach was used to estimate both 
incidence and mortality.(7) For incidence estimates, country-level rates were 
preferentially used when available. When country-wide population-based coverage was 
not available, a hierarchical approach was applied that incorporated regional data from 
mortality and mortality-to-incidence ratios (MIR), sub-national registry data, neighboring 
country or regional data and “all cancer” rates. Mortality estimates followed a similar step-
wise approach with six different methods used. Data included country-level rates when 
available, incidence estimates modeled on country-specific survival, or neighboring 
country/regional data. A complete description of GLOBOCAN methods has been 
published.(13) 
 
The GBD study group used a uniform approach to mortality and incidence estimation.(28, 
31) Cancer mortality was estimated in an ensemble modeling approach where different 
combinations of covariables and model types are used.(32) Data inputs used to estimate 
mortality from the MIR included vital registration system data, verbal autopsy data and 
cancer registry incidence data. Socio-demographic index (SDI), a summary measure of 
a location’s income-per-capita, average educational attainment, and fertility rate, was 
used as the predictive covariate in the MIR modeling to reflect a location’s development 
status.(31) In the ensemble model, covariates are ranked based on the strength of 
evidence for their causal connection. Hepatitis B prevalence in liver cancer for example, 
was a level one covariate, whereas education was a level three. Individual mortality 
estimates in the GBD are adjusted to separately estimate all-cause mortality to ensure 
that the estimated number of deaths due to single causes does not exceed the all-cause 
mortality. Incidence in the GBD is estimated by using again the separately modeled MIR 
for each estimated cancer type, age group, sex, year and location and dividing the 
mortality estimates by these MIR.  
 
Differences between GLOBOCAN and GBD results 
 
To compare differences between the estimates from GLOBOCAN(33) and GBD(34), 
open-access data comprising national, regional and global incidence and mortality data 
were downloaded from the online analysis portals maintained by both programs 
(appendix page 3). For GBD, the 2016 published estimates for the year 2012 were used 
for all data presented.(14) Descriptive statistics were used to generate relative 
proportions by cancer type from the absolute incidence and mortality figures, and 95% 
confidence ellipses(35) were computed from country level GLOBOCAN and GBD 
incidence and mortality rates using R version 3.4.3.  
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Estimates for the 2012 global annual incidence of all childhood cancers, ages 0-14 years, 
ranged from 163,284 from GLOBOCAN to 184,856 from GBD. Table 3 shows the 
incidence, mortality, and concordance of childhood cancer estimates from GLOBOCAN 
and GBD by topography and rank (ordered based on the incidence from SEER).(1) Nearly 
one-third of childhood cancers in both studies remained uncategorized, meaning these 
cancers were counted as part of an aggregated “other cancer” group in the GBD or 
included in the total but not in the detailed cancer list in GLOBOCAN. Among the specific 
cancer groups, the GBD estimates are generally higher, although GLOBOCAN estimates 
were higher for Hodgkin lymphoma and kidney cancers.  
 
In Figure 2, cancer incidence and mortality are presented for the WHO world regions, as 
estimated by GLOBOCAN and GBD. The proportion of incident cancers and deaths by 
cancer type were similar for five of the six regions with the notable exception of the African 
region, where Kaposi’s sarcomas (only available in the GLOBOCAN as GBD does not 
report Kaposi’s Sarcoma) and non-Hodgkin lymphomas are reported as more common. 
When the absolute numbers of new incident cases and deaths are compared, substantial 
inter-study regional variation is observed. Results range from similar estimates in Europe 
to a nearly two-fold greater number of incident new cancers as estimated by GBD in the 
WHO Western Pacific region compared to GLOBOCAN. Figure 3 displays the absolute 
number of overall incident cancer cases and cancer deaths but recategorized according 
to 2012 World Bank Income Status (low-income, low middle-income, upper middle-
income and high income). When categorized as all LMIC groups vs HIC, GLOBOCAN 
and GBD estimates are similar with 82.1% and 83.3% of incident cases and 93.5% and 
93.9% of deaths occurring in LMIC, respectively.  
 
Figure 4 displays the concordance between GLOBOCAN and GBD incidence and 
mortality rates for all childhood cancers combined, by country and World Bank income 
categories, which classify countries as low, low-middle, upper-middle and high-
income.(36) The mean of the national childhood cancer incidence and mortality rates for 
countries within each World Bank income group are broadly concordant. At the country 
level, however, the size of the 95% confidence ellipses underscores the wide discordance 
between the two model-based approaches to estimating the burden of childhood cancer 
for ages 0-14 years. The concordance of both studies is illustrated in panel A, which 
shows that higher incidence rates were estimated for HIC and that the mean incidence 
rates for low-income countries and low-middle income countries were lower and fell 
outside the confidence ellipse for HIC. In panel B, the LMIC rates for all three categories 
appear to cluster while HICs have a lower mortality rate compared to the other categories, 
though the mean remains within all three LMIC confidence ellipses.  
 
Cautions in using both model-based approaches as related to childhood cancer burden 
estimation 
 
The GBD and GLOBOCAN burden estimates are routinely cited as authoritative, but they 
should be used cautiously when applied to cancers among children because of important 
methodological limitations affecting pediatric cancer burden estimation. First, both studies 
share an important gap with respect to pediatric cancer epidemiology: nearly one-third of 
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these cancers are not individually estimated by either group. This is due to the selection 
of ICD categories, based on cancer primary site and not histology, to present the data. 
While topography-based ICD cancer codes are appropriate to present the bulk of cancer 
burden in the total population, it is not adapted to appropriately characterize cancer 
among children. Cancers in children and adults are histologically, biologically and 
epidemiologically distinct, so use of the ICCC-3 classification system would be more 
appropriate when estimating the burden among younger patients. Such a shift would also 
allow for a more applicable selection of covariates given the paucity of described 
environmental risk factors for childhood cancer. 
 
Perhaps the most obvious example for which specific approaches to estimation of the 
childhood and adolescent cancer burden would be most beneficial is with the types of 
cancers estimated and how they are classified. The major difference with respect to 
classification between the two studies is that the country-level estimates available from 
GLOBOCAN aggregate all leukemias while GBD provides separate estimates for ALL, 
AML, and chronic myeloid leukemia (CML). A sub-analysis of leukemia subtypes using 
GLOBOCAN and CI5 data provides global trends and proportions of leukemia subtypes 
for children ages 0-14 in 54 countries.(37) However, modeled data with country-specific 
estimates were not included in the analysis.  
 
In terms of estimation approaches, neither study effectively describes the burden of extra-
cranial solid tumors in children. GLOBOCAN and GBD both produce estimates of cancer 
incidence and mortality on the basis of topographic codes for children ages 0-14 years, 
so the frequency of childhood cancers with very specific morphology, such as Wilms’ 
tumor and hepatoblastoma, must be inferred based on age and organ of origin such as 
“kidney” or “liver” cancer. Furthermore, neither study estimates the incidence or mortality 
of neuroblastoma, osteosarcoma, Ewing sarcoma, or retinoblastoma, instead placing 
them into an “other cancer” group. Taken together, extra-cranial solid tumors represent 
17% of childhood cancers in HIC and they probably account for a large proportion of the 
uncategorized childhood cancers in Table 1. This is particularly relevant due to the 
growing body of genetic predisposition data and observed variations in the global 
incidence of solid tumors among children.(20, 38) Additionally, although in the GBD study 
years-lived with disability (YLDs) and DALYs are estimated, up to now, these estimates 
have not taken into account the specific long-term treatment associated chronic health 
conditions that occur in childhood cancer survivors.(39-41) Finally, although GBD 
categorizes all pediatric data, inclusive of the adolescent group, into 5-year age groups, 
GLOBOCAN provides estimates for broad age groups of 0-14, 15-39, 40-44 years and so 
forth, focusing on the age groups with the largest cancer burden. A recently published 
manuscript focusing on the global burden of cancer among AYA patients utilized 
GLOBOCAN methods and has reported global incidence and mortality outcomes for the 
20- to 39-year age group.(42)  
 
Beyond differences in data preparation and modeling methods, a key gap with no obvious 
solution that remains a critical void is how to estimate the expected number of children 
who develop cancer globally each year. In countries with registries where access to 
complex diagnostics is limited, misdiagnosis and missed diagnoses may both result in 
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underestimation of the true cancer burden. This is particularly important when interpreting 
GLOBOCAN estimates as they are a reflection of the true diagnosed cancers. GBD 
attempts to quantify the total underlying burden – diagnosed and undiagnosed by 
adjusting for so-called “garbage codes” (causes of death that should not be coded as the 
underlying cause of death or undefined codes like ICD-10 code R99 “Ill-defined and 
unknown cause of mortality”). However, even this method has limitations as it is likely that 
some deaths due to childhood cancer are miscoded as infectious, especially in limited-
resource settings. Estimating this effect is not a simple issue to remedy but will hopefully 
improve with better data through increasing diagnostic capacity and access to care, as 
well as through the validation of additional covariates when modeling pediatric cancer 
incidence. 
 
An appreciation of all these limitations is critical when interpreting childhood cancer 
burden estimates. For example, an examination of the mean rates of incidence by income 
category in figure 4A suggests a correlation between increasing income status and cancer 
incidence. At face value, this would suggest children in lower income countries are at 
lower risk of developing cancer. Attempts to explain this trend have suggested that global 
variations in mortality under the age of 5 years and inherited genetic predispositions to 
cancer are likely to be the cause.(2) However, if the reported data are due to an 
underdiagnoses, through likely misidentified or never identified new cases or deaths, the 
interpretation changes. Thus, investigators should not assume that the available 
estimates reflect the true incidence of childhood cancer in LMIC. Rather, these data 
should be interpreted as the number of cases of childhood cancer being identified and 
seeking treatment within the health system, a still important finding with practical health-
services planning implications.  
 
Recommendations by the authors to improve estimation methods for the global 
cancer burden in children and adolescents 
 
The objectives and methodology in the four described studies differ in important ways. 
Although the IICC-3, CONCORD-3, GLOBOCAN, and GBD studies represent the four 
most comprehensive sources for estimates of childhood cancer incidence, survival, and 
mortality, a complete set of global data is unavailable. Over the past decade, several 
articles have used the GLOBOCAN data in particular to emphasize the global burden of 
childhood cancer in the absence of adapted sources.(2, 43, 44) However, there is a need 
to critically compare or appraise the methods currently used and propose improvements 
in the current estimation approaches used.  
 
Panel 1 presents a list of proposed steps and initiatives as recommended by the authors 
to improve pediatric cancer burden estimates. These recommendations do not represent 
a formal consensus statement but were developed through several rounds of iterative 
input and agreement from all co-authors. Fundamental to robust estimates is high-quality 
observed data from population-based general or pediatric cancer registries that can 
represent the basis of evidence-based childhood cancer control plans. Given the paucity 
of quality-assured incidence data in LMIC, technical assistance to governments is needed 
to enable generation and use of their own data, including national estimates derived from 
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these data sources and timely application of best practices in order to improve the quality 
of reported registry data (i.e., reporting delay adjustments).(45) There is an overwhelming 
need for a multi-stakeholder action plan that emphasizes the use of observed data 
through increasing childhood cancer registry capacity in LMIC to inform dedicated 
childhood cancer control plans. The Global Initiative for Cancer Registration 
Development,(46) led by IARC with multiple global partners, represents an example of 
such an initiative. 
 
Incorporating childhood cancer into the global prioritization framework and developing 
more high-quality population-based cancer registries is a critical long-term investment, 
although the short-term step in improving current estimates should involve use of adapted 
cancer categories such as the ICCC whenever ICD-O-3 data is available.(17) Due to 
small numbers, many childhood cancers are currently grouped into broad categories that 
are not clinically meaningful. For example, leukemias, lymphomas, central nervous 
system tumors and other heterogeneous tumor subgroups should be defined by a 
common standard (currently ICCC-3) and categorized into subgroups that are relevant 
from a public health and clinical perspective. The most obvious example where this is 
relevant is when overview studies collapse ALL and AML into a single “leukemia” 
category. Although these two diagnoses are often grouped together, based on historic 
convention and small numbers due to the low ALL compared to AML incidence in the 
adult population, they are different cancers with a substantial burden among children, and 
hence, should be reported separately for health planning purposes. However, simply 
applying all 48 ICCC-3 categories in order to eliminate the proportion of uncategorized 
cancers noted in the GLOBOCAN and GBD studies is not a viable solution given the small 
numbers of childhood cancers and the large number of different rare cancer pathologies. 
Thus, careful appraisal of how categories are currently grouped, particularly for the 
unspecified and other specified neoplasms, is an important exercise that should be 
conducted and justified by each overview study. 
 
Reexamination of the adapted cancer categorization systems themselves such as ICCC-
3 is also needed. For example, lymphoblastic lymphomas, currently classified with other 
non-Hodgkin lymphomas based on historic convention, would be better categorized with 
ALL, given the similar biology and treatment. Similarly, segregating embryonal tumors, 
low-grade gliomas and high-grade gliomas as distinct central nervous system categories 
is important given the required health services and expected clinical outcomes associated 
with each. These recommendations would not require substantial effort, because the ICD-
O-3 classification system already make these classification categories feasible. 
 
Moreover, without access to multidisciplinary treatments, including cytotoxic 
chemotherapies, radiation, surgery and high-quality supportive care, childhood cancer is 
a fatal disease. Thus, incidence data, while critical for health services planning, need to 
be paired with access and outcomes data when contextualizing the disease burden.  Yet, 
high-quality childhood cancer registries and vital registration systems data remains the 
biggest impediment to accurate estimation of the childhood cancer burden.  
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Finally, while estimates of the cancer burden derived from models cannot replace the real  
observed data, they can help galvanize interest and to advocate the need for observed 
data with wider coverage and higher quality. In assessing the current state and future 
evolution of the childhood cancer burden, it would also be important to include variables 
such as disease stage at diagnosis, abandonment of treatment, and follow-up of all 
registered patients for their vital status. The definition of internationally acceptable 
standards, such as the Toronto guidelines on staging of childhood cancers,(47) 
represents a promising movement in this direction. Finally, creation of cancer registration 
training curricula that are specific for childhood cancer, at a level suitable for registrars 
and data entry specialists, represents an important remaining need in the field.(48) 
 
Childhood cancer burden estimates: Policy implications 
 
With the advent of the Sustainable Development Goals(49) and the global drive towards 
universal health coverage by 2030, the World Health Assembly recently adopted the 
global cancer challenge resolution in May 2017, an important event that added cancer 
prevention and control initiatives for all age ranges to the Global Action Plan for the 
Prevention and Control of Non-Communicable Diseases 2013-2020.(50) As a first step 
towards developing action plans to address disparities in cancer control both locally and 
globally, a better understanding and appreciation of the differences and gaps in current 
global childhood cancer burden estimates is an important prerequisite. For countries 
where population-based cancer registries exist, the observed data from these sources 
may be sufficient to guide efforts. However, among countries not covered by a 
participating registry in the IICC-3 or CONCORD-3 studies, the GLOBOCAN or GBD 
estimates of incidence, mortality and adjusted-life years are potentially the only data 
available. The variability of the estimates, highlighted in figure 4, should serve as an 
incentive to establish suitable surveillance systems in each country.  
 
Although several publications have recently demonstrated that childhood cancer 
treatment is cost-effective,(51) affordability and financial toxicity are also known barriers 
to successful pediatric cancer control initiatives that require policy interventions.(52, 53) 
The private sector has provided a significant amount of funding to support childhood 
cancer treatment programs in LMIC.(54, 55) If organizations were armed with accurate 
historic and current burden statistics, presented in an accessible and visually intuitive 
manner, they could leverage these data to improve education initiatives and expand 
fundraising efforts by demonstrating real or potential impact to donors.  Country case-
examples suggest governments can also be swayed to increase access to care by 
disease burden metrics. For example, in response to a 2009 clinical study that reported 
the survival and costs associated with treating children with ALL, the Chinese Ministry of 
Health decided in 2010 to provide governmental funding to treat all children with the 
disease.(56)    
 
Conclusions 
 
Cancers in children and adolescents are fundamentally different from the cancers seen 
in adults. To improve the relevance and quality of information on childhood cancer 
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burden, data collection and analytic approaches that are specific for children and 
adolescents, not tied to the methods used to estimate the adult cancer burden, are 
required. This proposed approach to delink adult and pediatric cancer estimates would 
allow for additional flexibility and innovation. Some improvements to the measurement of 
the disease burden could be implemented quickly, but structural changes will require both 
time and new financial resources. These include expanding the coverage of childhood 
cancer registration, especially in LMIC; enhancing the quality of data collection through 
capacity-building and standardized data dictionaries; and development of training 
curricula for tumor registrars that are specifically tailored to the registration of cancers in 
children and adolescents.   
 
A patchwork of estimates of the global burden of childhood and adolescent cancer is 
available, but they are either based on data covering only about a tenth of the world 
childhood population or are not adapted for this age-range. Thus, the results from these 
sources are highly heterogeneous. Due to the substantial differences between the 
estimates, making confident decisions on health policy, priority setting, and cancer control 
strategy and financing based on the available information is currently a challenging 
prospect.  
 
 14 
Table 1: Comparison of Currently Available Data on Global Pediatric Cancer Burden Approaches  
 IICC-3(12) GLOBOCAN 2012(13) GBD 2016(26) CONCORD-3(15) 
Publication year 2017 2015 2017 2018 
Years included in study 2001-2010 2012 1990-2015 2000-2014 
Coordinating Organization IARC  IARC Institute for Health 
Metrics and Evaluation 
Cancer Survival Group, 
London School of 
Hygiene and Tropical 
Medicine 
Global estimates  Not applicable Yes Yes Not applicable 
Number of registries included 153 375 562 322 
    Proportion of registries in low and  
    low-middle income countries* 
11% 7% 12% 5% 
Countries/territories Included 62 184 195 71 
Subnational geographical estimates No No Yes Yes 
Age strata (years) 0-4, 5-9, 10-14, 15-19 0-14 0-4, 5-9, 10-14, 15-19 0-14 
Outcomes estimated Incidence Incidence, mortality Incidence, prevalence, 
mortality, disability-
adjusted life years 
5-year net survival 
Classification**  ICCC-3  ICD-10 (selected sites 
and subsites) 
ICD-9 and ICD-10 ICD-O-3 
Cancers included*** Leukemias****,****** 
Lymphomas, CNS 
tumors, Neuroblastoma, 
Retinoblastoma, Kidney, 
Hepatic, Bone, Soft 
Tissue, Germ cell, 
Epithelial tumors, Other 
and unspecified 
Leukemias****, Hodgkin, 
NHL, CNS, Kidney*****, 
Liver*****, Kaposi 
Sarcoma 
ALL, AML, Hodgkin, NHL, 
CNS, Kidney*****, 
Liver***** 
Acute lymphoblastic 
leukemia******, 
Lymphomas, CNS tumors 
Uncategorized cancers (%) 0% 30% 29% Not applicable 
Annual estimate of the global 
number of incident cases in age 
range 0-19 years 
Not applicable 163,284 240,942 Not applicable 
Annual estimate of the global 
number of cancer deaths in age 
range 0-19 years 
Not applicable 79,956 90,075 Not applicable 
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IACR: International Association of Cancer Registries, IARC: International Agency for Research on Cancer; ICCC-3: International Classification of 
Childhood Cancer, Third Edition; ICD-9: International Classification of Diseases, Ninth Revision; ICD-10: International Classification of Diseases, 
Tenth Revision; ICD-O-3: International Classification of Diseases for Oncology, Third Edition;  
*  Low income and low middle-income country percentages calculated based on World Bank Fiscal Year 2018. Upper-middle income countries not 
included in the proportions reported.  
**Cancer coding may differ between the original data and the categories according to which they are presented.  
***ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; CNS: Central nervous system tumors; NHL: Non-Hodgkin lymphomas. ****ALL 
and AML not estimated separately;  
*****Kidney/Liver: Topographic codes in GLOBOCAN and GBD, Histology included in IICC-3.  
******Leukemias were further stratified into ALL and AML in a CONCORD-2 sub-analysis and in the open-access online data from IICC-3. 
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Table 2: Differences between the methods for modeling incidence and mortality in GLOBOCAN 2012 
and GBD 2016 
Study GLOBOCAN 2012(13) Global Burden of Disease 2016(26) 
Data sources Cancer Incidence in Five Continents X 
Individual population-based cancer 
registries 
WHO vital statistics 
Survival data 
Cancer Incidence in Five Continents V-X 
Individual population-based cancer 
registries 
Vital statistics (both WHO and national) 
Verbal autopsies 
Data quality 
criteria for 
inclusion 
Same as in the data sources; method of 
estimation adapted to the quality of 
available data 
None. GBD estimation methods correct for 
sampling and non-sampling errors. 
 
Incidence 
estimation 
Estimates based on best available 
information from (sub-)national population-
based cancer registries and vital statistics of 
the index country or region  
Based on modeled mortality estimates using 
separately modeled mortality-to-incidence 
ratios  
Mortality 
estimation 
Estimation from local, regional, pooled and 
neighbor countries’ mortality or from 
incidence estimates and survival 
Cause of death “ensemble” models using 
mortality data inputs as well as cancer 
registry incidence inputs that have been 
transformed to mortality estimates using 
separately modeled mortality-to-incidence 
ratios; models use various covariables and 
constrain the sum of the cause-specific 
mortality rates to the total mortality from all 
causes combined 
Uncertainty 
estimates  
No Yes 
Key limitations 
of the cancer 
burden 
estimates for 
LMIC  
Data presented according to ICD site codes, 
which do not reflect with the major 
childhood cancer diagnostic groups.  
 
Information from pediatric cancer registries 
was not considered.  
Data presented according to ICD site codes, 
which do not reflect with the major 
childhood cancer diagnostic groups.  
 
Information from pediatric cancer registries 
was not considered. 
 
Adult mortality-to-incidence ratios were 
used to estimate childhood cancer 
incidence from childhood mortality data.  
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Table 3: Differences between GLOBOCAN and GBD in the global estimates of new cases and deaths from 
cancer in children (0-14 years) in 2012, by ICD-10 topographic group 
  
  Number of cases   Number of deaths  
Malignancy ranked based on SEER 
incidence ages 0-14 years** 
GLOBOCAN 
2012 
Global Burden of 
Disease (GBD) 
2016 
(UI) 
Ratio****** GLOBOCAN 
2012 
Global Burden of 
Disease (GBD) 
2016 
(UI) 
Ratio****** 
Leukemias***  49,752 63,230 
(57,517-67,989) 
1·27  27,775 29,165 
(26,846-32,673) 
1·05 
Acute lymphoblastic leukemia  not estimated 30089 
(28,217-33,082) 
-  not estimated 12,489 
(11,429-14,828) 
- 
Acute myeloid leukemia  not estimated 11,631 
(10,376-13,178) 
-  not estimated 5,811 
(5,030-6,840) 
- 
Brain, nervous system tumors  20,105 29,967 
(27,612-32,022) 
1·49  10,458 15,828 
(14,066-17,532) 
1·51 
Neuroblastoma  not estimated not estimated -  not estimated not estimated - 
Non-Hodgkin lymphoma  16,514 17,350 
(14,722-18,746) 
1·05  7,223 10,974 
(9,195-12,375) 
1·52 
Kidney tumors (mostly Wilms’ 
tumor)**** 
 9,656 13,794 
(12,988-14,437) 
1·43  5,547 2,481 
(2,305-2,654) 
0·45 
Bone tumors  not estimated not estimated -  not estimated not estimated - 
Hodgkin lymphoma  6,744 5,220 
(4,270-5,946) 
0·77  1,737 2,421 
(1,798-3,069) 
1·39 
Rhabdomyosarcoma  not estimated not estimated -  not estimated not estimated - 
Retinoblastoma  not estimated not estimated -  not estimated not estimated - 
Categorized cancers  114,202 133,672 
(119,243-
146,284) 
1·17  57,861 62,503 
(54,630-71,192) 
1·08 
All cancers in age 0-14 years  163,284 184,856 
(171,441-
191,140) 
1·13  79,956 82,552 
(77,182-88,092) 
1·03 
Uncategorized cancers*****  49,082 51,184 
(46,850-54,878) 
1·04  22,095 20,048 
(18,287-22,478) 
0·91 
Proportion uncategorized  0·3 0·28 -  0·28 0·24 - 
 18 
GBD 2016 provided estimates of incidence and mortality for 195 countries, GLOBOCAN 2012 for 184 countries, so only countries included in both studies were 
included in the totals and the ratios. All estimates reflect 2012 figures.  
*UI: Study generated 95% uncertainty interval.  
** The order of malignancies in this table is ranked by the frequencies in data from SEER, where incidence is presumed to be complete and is structured 
specifically for childhood cancers.  
***GLOBOCAN 2012 does not differentiate Leukemia based on WHO type. GBD 2016 estimates "other leukemias" in addition to ALL and AML.  
****Neither group estimates Wilms tumor as a separate entity, however, as Wilms tumors represent a substantial majority of childhood kidney cancers where 
reliable histopathology incidence data are available, kidney tumors in this age group were assumed to represent primarily Wilms’ tumors.  
*****Uncategorized: cases included under "other neoplasms" category. 
******Ratio based on the absolute global number of row-specific childhood cancers reported in GBD to GLOBOCAN. 
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Figure 1: Global Pediatric Cancer Registry Coverage Based on Registries Contributing to the Final IICC-3 Study(11)* 
*The figure reflects the 308 high quality population-based cancer registries included in the study the IICC-3.  
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A. Incidence B.   Mortality 
 
 
Figure 2:  Proportion and Absolute Number of Cancer Cases in Children (Age 0-14 years) (A) Incidence and (B) Mortality by Type 
and World Health Organization (WHO) Region* 
Regional designations as defined by the WHO: AFR=African, AMR=Americas, EMR=Eastern Mediterranean, EUR= European, 
SEAR=Southeast Asia, WPR=Western Pacific; Leukemia NOS=Leukemia not otherwise specified. *Reference year 2012 data for GBD 
2016 were used to compare estimates between studies. 
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Figure 3: Absolute Number of Overall Cancer (A) Incidence and (B) Mortality 
Cases in Children (ages 0-14 years) by 2012 World Bank Low- and Middle-
Income Status* 
*Reference year 2012 data for GBD 2016 were used to compare estimates between 
studies. 
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Figure 4:  Overall Childhood (A) Incidence and (B) Mortality Rates in Children (ages 0-14 
years)*  
Dark shaded dots correspond to the median GLOBOCAN 2012 (x-axis) and GBD 2016 (y-axis) rates 
for incidence (Panel A) and mortality (Panel B) by countries categorized using the World Bank 
Income Groupings. Lighter shaded dots correspond to country-specific incidence (Panel A) and 
mortality (Panel B) rates, age-standardized per 100,000 children 0-14 years. 95% confidence ellipses 
correspond to the income group by color. Income groupings are based on the World Bank Fiscal Year 
2018; HIC: High Income Country, UMIC: Upper-Middle Income Country, LMIC: Lower-Middle Income 
Country, LIC: Low Income Country. All estimates based on incidence and mortality rates for the year 
2012. Mauritius was excluded from final figures and median calculations due to reported outlier rates 
but data is included in the appendix. *Reference year 2012 data for GBD 2016 were used to compare 
estimates between studies. 
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Panel 1: Recommendations from authors to improve estimates of the childhood cancer 
burden 
 
 Support existing cancer registries to improve the quality of childhood and adolescent 
ICD-O-3 data collected through quality control and quality assurance measures specific 
to the unique characteristics of cancer in younger patients. 
 
 Increase and improve follow-up of cancer patients, so that survival and its determinants, 
including treatment abandonment, can be measured. 
 
 Use observed incidence and survival data from cancer registries as baseline for 
estimates where possible. 
 
 Formulate frameworks and standards to encourage timely data sharing between 
hospital-based and population-based cancer registries on national level and global 
burden estimation groups on an international level. 
 
 Promote international data sharing for public health benefits while ensuring personal 
privacy rights. 
 
 Use cancer categories which are relevant for childhood cancers and clinically meaningful 
for both observed and modeled data, and report outcomes using the ICCC-3 groupings. 
Results should be reported separately for the subgroups of leukemia and lymphoma and 
CNS tumors should be reported by grading. Reports should include results for major 
solid tumors common in childhood age.  
 
 Develop models, using appropriate classification approaches, to forecast the expected 
changes in cancer incidence among children based on demographics shifts, potential 
reductions in non-communicable disease and diagnostic capabilities. 
 
 Develop statistical approaches to integrate data from large cancer survivorship studies in 
order to include cancer treatment related chronic health conditions when estimating 
DALYs. 
 
 Develop and disseminate technical guidelines that are specific for childhood cancer 
registration, including recommendations for collection of data on staging (aligned with 
Toronto consensus guidelines) and treatment (abandonment, modalities, palliation).  
 
 Ensure timely mapping between ICD-O and ICCC systems by taking into consideration 
pathological and clinical characteristics as well as continuity across time when defining 
classes and sub-classes for analysis and reporting. 
 
 Create and disseminate cancer registration training curricula and opportunities that are 
specific for childhood cancer. 
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